

## *Real-world evidence of mortality and survival rates in 256 individuals with APDS.*

Jennifer Hanson<sup>1</sup> and Penelope E. Bonnen<sup>1\*</sup>

1. Department of Molecular and Human Genetics, Baylor College of Medicine,  
Houston, Texas, USA

\*Correspondence to: Dr. Penelope E Bonnen ([pbonnen@bcm.edu](mailto:pbonnen@bcm.edu)) 713-798-4256

**Keywords:** activated PI3K delta syndrome, APDS, PIK3CD, PIK3R1, primary immune deficiency, PID, common variable immune deficiency, CVID, PI3-kinase

## Abstract

Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is a rare genetic disorder that presents clinically as a primary immunodeficiency. Clinical presentation of APDS includes severe, recurrent infections, lymphoproliferation, lymphoma and other cancers, autoimmunity and enteropathy. Autosomal dominant variants in two independent genes have been demonstrated to cause APDS. Pathogenic variants in *PIK3CD* and *PIK3R1*, both of which encode components of the PI3-kinase, have been identified in subjects with APDS. APDS1 is caused by gain of function (GOF) variants in the *PIK3CD* gene while loss of function (LOF) variants in *PIK3R1* have been reported to cause APDS2. We conducted a review of the medical literature and identified 256 individuals who had a molecular diagnosis for APDS as well as age at last report; 193 individuals with APDS1 and 63 with APDS2. A Kaplan-Meier survival analysis for APDS showed the conditional survival rate at the age of 20 was 87%, age 30 was 74%, age 40 and 50 were 68%. Review of causes of death showed that the most common cause of death was lymphoma, followed by complications from HSCT. The mortality data suggests that the standard of care treatment for APDS, immunoglobulin replacement therapy, appears to prevent most deaths due to severe infection, however, new treatments are needed to mitigate the risk of death from lymphoma and other cancers. This analysis based on real world evidence gathered from the medical literature is the largest study of survival for APDS to date.

## Introduction

Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is a rare genetic disorder that presents clinically as a primary immunodeficiency. Autosomal dominant variants in two independent genes have been demonstrated to cause APDS. Pathogenic variants

in *PIK3CD* and *PIK3R1*, both of which encode components of the PI3-kinase, have been identified in subjects with APDS. APDS1 is caused by gain of function (GOF) variants in the *PIK3CD* gene, while loss of function (LOF) variants in *PIK3R1* have been reported to cause APDS2<sup>1-4</sup>. The pathogenic variants *PIK3CD* and *PIK3R1* result in the over activation of PI3-kinase. PI3-kinase plays a role in regulation of T and B cells, therefore, both APDS1 and APDS2 manifest as combined immunodeficiency. Clinical presentation of APDS typically begins in the first year of life as severe, recurrent infections. This progresses to include lymphoproliferation and sometimes malignant lymphoma; many patients also experience autoimmunity and enteropathy<sup>5</sup>.

Treatment for APDS often includes immunoglobulin replacement therapy to combat recurrent infection, as well as immunosuppressive agents such as rituximab, sirolimus and tacrolimus to mitigate autoimmunity and lymphoproliferation<sup>5</sup>. Hematopoietic stem cell transplantation (HSCT) has also been undertaken in a minority of patients and has been shown to ameliorate symptoms, however, HSCT itself can also cause adverse complications and death<sup>5-8</sup>.

Despite available treatments, survival for individuals with APDS appears to be shortened from the average lifespan<sup>6;7</sup>. Okano *et al* reported on APDS1 survival based on 23 Japanese and Taiwanese patients from 21 families, 9 of which had HSCT<sup>6</sup>. Thirty-year survival was 83% with just 2 deaths, both due to HSCT. Elkaim *et al* reported that the thirty-year survival rate of APDS2 was 83%, based on an international cohort of 36 patients<sup>7</sup>.

We conducted a review of the medical literature for every published case of APDS with documented age at last report and a molecular diagnosis in *PIK3CD* or *PIK3R1*. We identified 256 individuals who had a molecular diagnosis for APDS as well as age at last

report; 193 individuals with APDS1 and 63 with APDS2. A comprehensive survival analysis and study of causes of death for APDS was conducted. The results of this study show decreased survival compared to previous reports, which may be attributed to the sample size of this study being more than 7x higher than prior studies.

## Methods

### *Literature review and data extraction*

Literature was reviewed for all reports of age of individuals with APDS. All individuals included in this analysis were published in English language peer-reviewed journals indexed in PubMed. Search terms utilized were PIK3CD, PIK3R1, PASLI, APDS. In order to be included in this study an individual had to have been reported to have a molecular diagnosis of pathogenic variant in either PIK3CD or PIK3R1. Age at last report was an additional requirement to be included in this study. In addition, cause of death and whether the individual received HSCT were also noted when available. In total, 116 papers were reviewed. Last access date was 08-01-2022. Through this review of the medical literature, 193 individuals diagnosed with APDS1 through molecular genetic testing and pathogenic variant present in *PIK3CD* were extracted from the literature for whom age was reported. In addition, 63 individuals diagnosed with APDS2 through molecular genetic testing and pathogenic variant present in *PIK3R1* were extracted from the literature for whom age was reported.

### *Kaplan-Meier survival analysis*

Kaplan-Meier survival analysis was conducted using the R survival package to estimate the probability of survival over time plus the 95% confidence interval<sup>9-11</sup>. All-cause mortality was considered the endpoint. Any individual who was alive at last report was censored. A censored observation is one where the subject drops out of the study but

survives at a given time point. Kaplan-Meier survival analysis was conducted using 1-year age bins from birth to the oldest patient age. The Mantel-Haenszel test was utilized to test if the conditional probability estimates from APDS1 and 2 were different from each other <sup>12</sup>.

## Results

We reviewed the literature for all reports of age of individuals with APDS. Through this review of the medical literature, 193 individuals diagnosed with APDS1 through molecular genetic testing and pathogenic variant present in *PIK3CD* were extracted from the literature for whom age was reported <sup>1; 2; 6; 8; 13-54</sup>. In addition, 63 individuals diagnosed with APDS2 through molecular genetic testing and pathogenic variant present in *PIK3R1* were extracted from the literature for whom age was reported <sup>3; 4; 7; 8; 26; 44; 55-66</sup>.

The median age of individuals reported with APDS1 was 13 years with an average of 17 years (range, 1 - 64 years). The median age of individuals reported with APDS2 was 14 years with an average of 16 years (range, 1 - 56 years). The age distribution was significantly different between the two groups due to there being disproportionately more individuals with APDS1 in the 5 – 15 year age range ( $p = 3.6E-10$ ) (Figure 1). Gender was not available for all individuals in the study. For APDS1, 103/182 (57%) individuals were reported as being male and 79/182 (43%) individuals were noted to be female. For APDS2, 20/39 (51%) individuals were reported as being male with 19/39 (49%) individuals were noted to be female.

Twenty-four individuals with APDS1 in this study were reported as being deceased. Age of death ranged from 1 - 64 years. The most common cause of death was tied between lymphoma (N = 5) and HSCT (N = 5) (Figure 2). The range of ages for death by lymphoma

was 1 – 27 years, while the range of ages for death by HSCT was 5 – 18 years. The next most common cause of death was sepsis with no further information specified (N = 3, age range 11 – 31 years). Additional causes of death included: Varicella zoster pneumonitis (N = 1, age 12); Acute myeloid leukemia (N = 1, age 22); lymphoproliferative disease (N = 1, age 11); gastric cancer (N = 1, age 64); IgA nephropathy (N = 1, age 57); respiratory failure (N = 1, age 39) (Figure 2).

Five out of the 63 individuals with APDS2 in this study were reported as having died. Age of death ranged from 12 - 36 years. The cause of death was reported for 4/5 individuals who died with APDS2 and all four of their deaths were attributed to lymphoma.

Kaplan-Meier survival analysis was conducted that allowed for inclusion of individuals who were alive at last report as well as those who died during the timespan of the study. Kaplan-Meier survival analysis was conducted for all-cause mortality in 1-year age bins on subjects diagnosed with APDS1 and separately for subjects diagnosed with APDS2 (Figure 3). The survival probability estimate for APDS1 at the age of 20 was 87%, age 30 was 75%, age 40 and 50 was 69%. The survival probability estimate for APDS2 at the age of 20 was 98%, age 30 was 72%, age 40 and 50 was 60%. The Mantel-Haenszel test showed that the survival probability estimates for APDS1 and APDS2 were not different from each other (p-value: 0.49). Consequently, Kaplan-Meier survival analysis was also conducted on the combined APDS1-2 cohort using age at last report for 256 individuals, since the combined cohort was largest and had the most power (Figure 3). Because most of the individuals in the combined cohort had APDS1 the survival curve for APDS1-2 most closely reflected the survival curve for APDS1. For APDS1-2 the conditional survival rate at the age of 20 was 87%, age 30 was 74%, age 40 and 50 was 68%.

## Discussion

Kaplan-Meier survival analysis and studies of mortality was conducted for 256 individuals who had genetically defined APDS1 or 2. Kaplan-Meier survival analysis on the combined APDS1-2 cohort using age at last report showed that the APDS1-2 the conditional survival rate at the age of 20 was 87%, age 30 was 74%, age 40 and 50 was 68%.

In this cohort of 256 individuals with APDS1 or APDS2, 29 deaths were noted. Of these, the cause of death was reported for 23 individuals. The most common cause of death was lymphoma with age of death from lymphoma ranging from 1 – 27 years. The second most common cause of death was complications resulting from HSCT. Of the individuals who reached older ages, the causes of death were gastric cancer (age 64), IgA nephropathy (age 57), and respiratory failure (age 39). Most deaths occurred before the age of 30, however, it is important to note that the age distribution of this cohort is highly skewed toward younger ages with 85% of the combined APDS cohort in this study being less than 30 years old.

Given that only 15% of the cohort was older than 30, this study has less power beyond the age of 30. This is reflected in the larger confidence intervals in the Kaplan Meier curves post-30, as well as the dearth of deaths after age 30 in the chart in Figure 2B. The chart could be misconstrued to indicate that there are fewer deaths after the age of 30, however, the data from this cohort simply does not provide the opportunity to make observations post-age 30 with as much sensitivity as below age 30. Having noted this limitation, this cohort contained 38 individuals 30 years or older which is larger than the total study size of the two previous survival analyses published for APDS.

There are two previously published survival analyses for APDS, one for APDS1 and one for APDS2 <sup>6,7</sup>. With much smaller sample sizes than this study, just N = 23 for APDS1 <sup>6</sup> and N = 36 for APDS2 <sup>7</sup>, both reported thirty-year survival was 83%. In this study with a much larger cohort, N = 256, the thirty-year survival was 74%. The lower survival rates in this study is likely due to the larger sample size of this cohort resulting in greater sensitivity to observe events and consequently in a more robust measure of survival rates.

Common variable immune deficiency (CVID) is a heterogenous group of primary immune deficiencies clinically-defined as having reduced IgG, IgA, and/or IgM. There are multiple genetic causes of CVID with *PIK3CD* and *PIK3R1* being among them <sup>67</sup>. Kaplan-Meier survival analysis of a large cohort of 411 subjects with genetically undefined CVID who were followed for four decades was reported <sup>68</sup>. The 30-year survival rate for this CVID cohort was 68% for females and 70% for males. This more closely resembles the 74% thirty-year survival rate that was found in this study of APDS.

The most common causes of death in the CVID cohort were respiratory failure from chronic lung disease (37%), cancer (primarily lymphoma) (29%), and severe infection (10%) <sup>68</sup>. In contrast, lymphoma was the most common cause of death in this APDS cohort and only one person with APDS was reported as having died due to respiratory failure from chronic lung disease. This could indicate that respiratory failure is a less frequent feature of APDS than heterogenous CVID; however, it could also be that respiratory failure from chronic lung disease occurs at older ages, and as we noted this APDS cohort has 38/256 individuals who were older than 30. Longer term follow-up on APDS is warranted to better define survival and mortality at older ages.

The results of this study on survival and mortality in APDS suggest that the standard of care treatment for APDS, replacement immunoglobulin therapy, appears to prevent



most deaths due to severe infection, however, new treatments are needed to mitigate the risk of death from lymphoma and other cancers.

## References

1. Angulo, I., Vadas, O., Garcon, F., Banham-Hall, E., Plagnol, V., Leahy, T.R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013). Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. *Science* 342, 866-871.
2. Lucas, C.L., Kuehn, H.S., Zhao, F., Niemela, J.E., Deenick, E.K., Palendira, U., Avery, D.T., Moens, L., Cannons, J.L., Biancalana, M., et al. (2014). Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. *Nat Immunol* 15, 88-97.
3. Lucas, C.L., Zhang, Y., Venida, A., Wang, Y., Hughes, J., McElwee, J., Butrick, M., Matthews, H., Price, S., Biancalana, M., et al. (2014). Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. *J Exp Med* 211, 2537-2547.
4. Deau, M.C., Heurtier, L., Frange, P., Suarez, F., Bole-Feysot, C., Nitschke, P., Cavazzana, M., Picard, C., Durandy, A., Fischer, A., et al. (2014). A human immunodeficiency caused by mutations in the PIK3R1 gene. *J Clin Invest* 124, 3923-3928.
5. Jamee, M., Moniri, S., Zaki-Dizaji, M., Olbrich, P., Yazdani, R., Jadidi-Niaragh, F., Aghamahdi, F., Abolhassani, H., Condliffe, A.M., Aghamohammadi, A., et al. (2020). Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kdelta Syndrome (APDS): a Systematic Review. *Clin Rev Allergy Immunol* 59, 323-333.
6. Okano, T., Imai, K., Tsujita, Y., Mitsui, N., Yoshida, K., Kamae, C., Honma, K., Mitsui-Sekinaka, K., Sekinaka, Y., Kato, T., et al. (2019). Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase delta syndrome type 1. *J Allergy Clin Immunol* 143, 266-275.
7. Elkaim, E., Neven, B., Bruneau, J., Mitsui-Sekinaka, K., Stanislas, A., Heurtier, L., Lucas, C.L., Matthews, H., Deau, M.C., Sharapova, S., et al. (2016). Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: A cohort study. *J Allergy Clin Immunol* 138, 210-218 e219.
8. Nademi, Z., Slatter, M.A., Dvorak, C.C., Neven, B., Fischer, A., Suarez, F., Booth, C., Rao, K., Laberko, A., Rodina, J., et al. (2017). Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. *J Allergy Clin Immunol* 139, 1046-1049.
9. Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association* 53, 457-481.
10. Newcombe, R.G. (1998). Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. *Statistics in Medicine* 17, 857-872.
11. Wilson, E.B. (1927). Probable Inference, the Law of Succession, and Statistical Inference. *Journal of the American Statistical Association* 22, 209-212.
12. Mantel, N., and Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. *Journal of the National Cancer Institute* 22, 719-748.

13. Rao, V.K., Webster, S., Dalm, V., Sediva, A., van Hagen, P.M., Holland, S., Rosenzweig, S.D., Christ, A.D., Sloth, B., Cabanski, M., et al. (2017). Effective "activated PI3Kdelta syndrome"-targeted therapy with the PI3Kdelta inhibitor leniolisib. *Blood* 130, 2307-2316.
14. Crank, M.C., Grossman, J.K., Moir, S., Pittaluga, S., Buckner, C.M., Kardava, L., Agharahimi, A., Meuwissen, H., Stoddard, J., Niemela, J., et al. (2014). Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. *J Clin Immunol* 34, 272-276.
15. Kracker, S., Curtis, J., Ibrahim, M.A., Sediva, A., Salisbury, J., Campr, V., Debre, M., Edgar, J.D., Imai, K., Picard, C., et al. (2014). Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. *J Allergy Clin Immunol* 134, 233-236.
16. Hartman, H.N., Niemela, J., Hintermeyer, M.K., Garofalo, M., Stoddard, J., Verbsky, J.W., Rosenzweig, S.D., and Routes, J.M. (2015). Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis. *J Clin Immunol* 35, 11-14.
17. Chiriaco, M., Brigida, I., Ariganello, P., Di Cesare, S., Di Matteo, G., Taus, F., Cittaro, D., Lazarevic, D., Scarselli, A., Santilli, V., et al. (2017). The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. *Clin Immunol* 178, 20-28.
18. Elgizouli, M., Lowe, D.M., Speckmann, C., Schubert, D., Hulsdunker, J., Eskandarian, Z., Dudek, A., Schmitt-Graeff, A., Wanders, J., Jorgensen, S.F., et al. (2016). Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency. *Clin Exp Immunol* 183, 221-229.
19. Tsujita, Y., Mitsui-Sekinaka, K., Imai, K., Yeh, T.W., Mitsuiki, N., Asano, T., Ohnishi, H., Kato, Z., Sekinaka, Y., Zaha, K., et al. (2016). Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase delta syndrome-like immunodeficiency. *J Allergy Clin Immunol* 138, 1672-1680 e1610.
20. Maffucci, P., Filion, C.A., Boisson, B., Itan, Y., Shang, L., Casanova, J.L., and Cunningham-Rundles, C. (2016). Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency. *Front Immunol* 7, 220.
21. Rae, W., Ramakrishnan, K.A., Gao, Y., Ashton-Key, M., Pengelly, R.J., Patel, S.V., Ennis, S., Williams, A.P., and Faust, S.N. (2016). Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase delta syndrome. *Clin Immunol* 171, 38-40.
22. Rae, W., Gao, Y., Ward, D., Mattocks, C.J., Eren, E., and Williams, A.P. (2017). A novel germline gain-of-function variant in PIK3CD. *Clin Immunol* 181, 29-31.
23. Heurtier, L., Lamrini, H., Chentout, L., Deau, M.C., Bouafia, A., Rosain, J., Plaza, J.M., Parisot, M., Dumont, B., Turpin, D., et al. (2017). Mutations in the adaptor-binding domain and associated linker region of p110delta cause Activated PI3K-delta Syndrome 1 (APDS1). *Haematologica* 102, e278-e281.
24. Takeda, A.J., Zhang, Y., Dornan, G.L., Siempelkamp, B.D., Jenkins, M.L., Matthews, H.F., McElwee, J.J., Bi, W., Seeborg, F.O., Su, H.C., et al. (2017). Novel PIK3CD mutations affecting N-terminal residues of p110delta cause activated PI3Kdelta syndrome (APDS) in humans. *J Allergy Clin Immunol* 140, 1152-1156 e1110.
25. Stray-Pedersen, A., Sorte, H.S., Samarakoon, P., Gambin, T., Chinn, I.K., Coban Akdemir, Z.H., Erichsen, H.C., Forbes, L.R., Gu, S., Yuan, B., et al. (2017). Primary

- immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *J Allergy Clin Immunol* 139, 232-245.
26. Wentink, M., Dalm, V., Lankester, A.C., van Schouwenburg, P.A., Scholvinck, L., Kalina, T., Zachova, R., Sediva, A., Lambeck, A., Pico-Knijnenburg, I., et al. (2017). Genetic defects in PI3Kdelta affect B-cell differentiation and maturation leading to hypogammaglobulinemia and recurrent infections. *Clin Immunol* 176, 77-86.
  27. Dulau Florea, A.E., Braylan, R.C., Schafernak, K.T., Williams, K.W., Daub, J., Goyal, R.K., Puck, J.M., Rao, V.K., Pittaluga, S., Holland, S.M., et al. (2017). Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. *J Allergy Clin Immunol* 139, 1032-1035.e1036.
  28. Mettman, D., Thiffault, I., Dinakar, C., and Saunders, C. (2017). Immunodeficiency-Associated Lymphoid Hyperplasia As a Cause of Intussusception in a Case of Activated PI3K-delta Syndrome. *Front Pediatr* 5, 71.
  29. Saettini, F., Pelagatti, M.A., Sala, D., Moratto, D., Giliani, S., Badolato, R., and Biondi, A. (2017). Early diagnosis of PI3Kdelta syndrome in a 2 years old girl with recurrent otitis and enlarged spleen. *Immunol Lett* 190, 279-281.
  30. Coulter, T.I., Chandra, A., Bacon, C.M., Babar, J., Curtis, J., Screaton, N., Goodlad, J.R., Farmer, G., Steele, C.L., Leahy, T.R., et al. (2017). Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study. *J Allergy Clin Immunol* 139, 597-606 e594.
  31. Hong, C.R., Lee, S., Hong, K.T., Choi, J.Y., Shin, H.Y., Choi, M., and Kang, H.J. (2019). Successful haploidentical transplantation with post-transplant cyclophosphamide for activated phosphoinositide 3-kinase delta syndrome. *J Allergy Clin Immunol Pract* 7, 1034-1037 e1031.
  32. Luo, Y., Xia, Y., Wang, W., Li, Z., Jin, Y., Gong, Y., He, T., Li, Q., Li, C., and Yang, J. (2018). Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase delta syndrome. *Clin Immunol* 197, 60-67.
  33. Buchbinder, D., Seppanen, M., Rao, V.K., Uzel, G., and Nugent, D. (2018). Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes. *J Pediatr Hematol Oncol* 40, e319-e322.
  34. Pham, M.N., and Cunningham-Rundles, C. (2018). Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion. *Front Pediatr* 6, 402.
  35. Lougaris, V., Baronio, M., Moratto, D., Tampella, G., Gazzurelli, L., Facchetti, M., Martire, B., Cardinale, F., Lanzarotto, F., Bondioni, M.P., et al. (2019). A novel monoallelic gain of function mutation in p110delta causing atypical activated phosphoinositide 3-kinase delta syndrome (APDS-1). *Clin Immunol* 200, 31-34.
  36. Tessarin, G., Rossi, S., Baronio, M., Gazzurelli, L., Colpani, M., Benvenuto, A., Zunica, F., Cardinale, F., Martire, B., Brescia, L., et al. (2020). Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients. *J Clin Med* 9.
  37. Thauland, T.J., Pellerin, L., Ohgami, R.S., Bacchetta, R., and Butte, M.J. (2019). Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. *Front Immunol* 10, 753.

38. Baleyrier, F., Ranza, E., Schappi, M., Rougemont, A.L., Merlini, L., Ansari, M., and Blanchard-Rohner, G. (2019). Activated Phosphoinositide 3 Kinase Delta Syndrome (APDS): A Primary Immunodeficiency Mimicking Lymphoma. *J Pediatr Hematol Oncol* 41, e521-e524.
39. Cansever, M., Zietara, N., Chiang, S.C.C., Ozcan, A., Yilmaz, E., Karakukcu, M., Rohlf, M., Somekh, I., Canoz, O., Abdulrezzak, U., et al. (2020). A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma. *J Pediatr Hematol Oncol* 42, 156-159.
40. Wallace, J.G., Zambrano-Rodas, P., Cordova-Calderon, W., Estrada-Turriate, S., Mendoza-Quispe, D., Limache Ontiveros, Y., Geha, R.S., Chou, J., and Platt, C.D. (2020). Dysregulated actin dynamics in activated PI3Kdelta syndrome. *Clin Immunol* 210, 108311.
41. Ahmed, A.A., El Shahaway, A.A., and Hussien, S.A. (2020). Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency. *Allergol Immunopathol (Madr)* 48, 686-693.
42. Kang, J.M., Kim, S.K., Kim, D., Choi, S.R., Lim, Y.J., Kim, S.K., Park, B.K., Park, W.S., Kang, E.S., Ko, Y.H., et al. (2020). Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase delta Syndrome I: the First Case Series in Korea. *Yonsei Med J* 61, 542-546.
43. Lougaris, V., Baronio, M., Castagna, A., Tessarin, G., Rossi, S., Gazzurelli, L., Benvenuto, A., Moratto, D., Chiarini, M., Cattalini, M., et al. (2020). Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110delta. *Clin Immunol* 219, 108543.
44. Diaz, N., Juarez, M., Cancrini, C., Heeg, M., Soler-Palacin, P., Payne, A., Johnston, G.I., Helmer, E., Cain, D., Mann, J., et al. (2020). Seletalisib for Activated PI3Kdelta Syndromes: Open-Label Phase 1b and Extension Studies. *J Immunol* 205, 2979-2987.
45. Lu, M., Gu, W., Sheng, Y., Wang, J., and Xu, X. (2021). Case Report: Activating PIK3CD Mutation in Patients Presenting With Granulomatosis With Polyangiitis. *Front Immunol* 12, 670312.
46. Zhang, X., Wang, J., Zhu, K., Jin, Y., Fu, H., and Mao, J. (2021). Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. *J Int Med Res* 49, 3000605211013222.
47. Schworer, S.A., Francis, O.L., Johnson, S.M., Smith, B.D., Gold, S.H., Smitherman, A.B., and Wu, E.Y. (2021). Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review. *J Pediatr Hematol Oncol* 43, 281-287.
48. Bloomfield, M., Klocperk, A., Zachova, R., Milota, T., Kanderova, V., and Sediva, A. (2021). Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence. *Front Pediatr* 9, 697706.
49. Marzollo, A., Bresolin, S., Colavito, D., Cani, A., Gaio, P., Bosa, L., Mescoli, C., Rossini, L., Barzaghi, F., Perilongo, G., et al. (2021). Case Report: Intestinal Nodular Lymphoid Hyperplasia as First Manifestation of Activated PI3Kdelta Syndrome Due to a Novel PIK3CD Variant. *Front Pediatr* 9, 703056.
50. Yin, Z., Tian, X., Zou, R., He, X., Chen, K., and Zhu, C. (2021). Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase delta Syndrome. *Front Immunol* 12, 813261.

51. Wang, W., Min, Q., Lai, N., Csomos, K., Wang, Y., Liu, L., Meng, X., Sun, J., Hou, J., Ying, W., et al. (2022). Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene. *Front Immunol* 13, 890073.
52. Wang, Y., Wang, W., Liu, L., Hou, J., Ying, W., Hui, X., Zhou, Q., Liu, D., Yao, H., Sun, J., et al. (2018). Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase delta Syndrome. *J Clin Immunol* 38, 854-863.
53. Kannan, J.A., Davila-Saldana, B.J., Zhang, K., Filipovich, A.H., and Kucuk, Z.Y. (2015). Activated phosphoinositide 3-kinase delta syndrome in a patient with a former diagnosis of common variable immune deficiency, bronchiectasis, and lymphoproliferative disease. *Ann Allergy Asthma Immunol* 115, 452-454.
54. Goto, F., Uchiyama, T., Nakazawa, Y., Imai, K., Kawai, T., and Onodera, M. (2017). Persistent Impairment of T-Cell Regeneration in a Patient with Activated PI3K delta Syndrome. *J Clin Immunol* 37, 347-350.
55. Lougaris, V., Faletra, F., Lanzi, G., Vozzi, D., Marcuzzi, A., Valencic, E., Piscianz, E., Bianco, A., Girardelli, M., Baronio, M., et al. (2015). Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. *Clin Immunol* 159, 33-36.
56. Lawrence, M.G., and Uzel, G. (2015). 6-year-old boy with recurrent sinopulmonary infections and lymphadenopathy. *J Allergy Clin Immunol Pract* 3, 461-463 e461; quiz 464-465.
57. Kuhlen, M., Honscheid, A., Loizou, L., Nabhani, S., Fischer, U., Stepensky, P., Schaper, J., Klapper, W., Siepermann, M., Schuster, F., et al. (2016). De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly. *Clin Immunol* 162, 27-30.
58. Olbrich, P., Lorenz, M., Cura Daball, P., Lucena, J.M., Rensing-Ehl, A., Sanchez, B., Fuhrer, M., Camacho-Lovillo, M., Melon, M., Schwarz, K., et al. (2016). Activated PI3Kdelta syndrome type 2: Two patients, a novel mutation, and review of the literature. *Pediatr Allergy Immunol* 27, 640-644.
59. Martinez-Saavedra, M.T., Garcia-Gomez, S., Dominguez Acosta, A., Mendoza Quintana, J.J., Paez, J.P., Garcia-Reino, E.J., Camps, G., Martinez-Barricarte, R., Itan, Y., Boisson, B., et al. (2016). Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections. *Clin Immunol* 173, 117-120.
60. Asano, T., Okada, S., Tsumura, M., Yeh, T.W., Mitsui-Sekinaka, K., Tsujita, Y., Ichinose, Y., Shimada, A., Hashimoto, K., Wada, T., et al. (2018). Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kdelta Syndrome. *Front Immunol* 9, 568.
61. Petrovski, S., Parrott, R.E., Roberts, J.L., Huang, H., Yang, J., Gorentla, B., Mousallem, T., Wang, E., Armstrong, M., McHale, D., et al. (2016). Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature. *J Clin Immunol* 36, 462-471.
62. Dominguez-Pinilla, N., Allende, L.M., Rosain, J., Gallego, M.D.C., Chaves, F., Deswarte, C., Viedma, E., de Inocencio Arocena, J., Ruiz-Contreras, J., Bustamante, J., et al. (2018). Disseminated abscesses due to *Mycoplasma faucium* in a patient with activated PI3K $\delta$  syndrome type 2. *J Allergy Clin Immunol Pract* 6, 1796-1798.e1792.
63. Yazdani, R., Hamidi, Z., Babaha, F., Azizi, G., Fekrvand, S., Abolhassani, H., and Aghamohammadi, A. (2019). PIK3R1 Mutation Associated with Hyper IgM (APDS2

- Syndrome): A Case Report and Review of the Literature. *Endocr Metab Immune Disord Drug Targets* 19, 941-958.
64. Karanovic, D., Michelow, I.C., Hayward, A.R., DeRavin, S.S., Delmonte, O.M., Grigg, M.E., Dobbs, A.K., Niemela, J.E., Stoddard, J., Alhinai, Z., et al. (2019). Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase delta Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies. *Front Immunol* 10, 77.
  65. Ramirez, L., Tamayo, W., and Ale, H. (2020). APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant. *J Clin Immunol* 40, 1020-1025.
  66. Bravo García-Morato, M., García-Miñaur, S., Molina Garicano, J., Santos Simarro, F., Del Pino Molina, L., López-Granados, E., Ferreira Cerdán, A., and Rodríguez Pena, R. (2017). Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two. *Clin Immunol* 179, 77-80.
  67. Abolhassani, H., Hammarstrom, L., and Cunningham-Rundles, C. (2020). Current genetic landscape in common variable immune deficiency. *Blood* 135, 656-667.
  68. Resnick, E.S., Moshier, E.L., Godbold, J.H., and Cunningham-Rundles, C. (2012). Morbidity and mortality in common variable immune deficiency over 4 decades. *Blood* 119, 1650-1657.

## Figure Legends

Figure 1. Age at last report in a cohort of 256 individuals with APDS. The age at last report was plotted in 5-year age bins for individuals with a molecular diagnosis of pathogenic PIK3CD variant resulting in APDS1 (orange), and for those with a molecular diagnosis of pathogenic PIK3R1 variant (blue). The moving average of the age at last report was plotted for individuals with APDS1/PIK3CD in blue and for individuals with APDS2/PIK3R1 in orange.

Figure 2. Age and cause of death for APDS. A. Causes of death in individuals with APDS1 are shown and the size of the pie slice reflects the number of individuals with that cause of death. All individuals with APDS2 had the same cause of death, lymphoma, so it was not plotted. B. Cause of death in individuals with APDS1 and APDS2 was plotted with age of death on the x-axis and number of individuals plotted on the y-axis. The color scheme in A. and B. are the same, with each color indicating a different cause of death. The key for color to cause of death is shown in the figure.

Figure 3. Kaplan-Meier survival analysis of all-cause mortality in 256 individuals with APDS. A. The probability of survival over time plus the 95% confidence interval was plotted for individuals with APDS1, N = 193, and separately for B. APDS2, N = 63. The survival rate conditional on having either APDS1 or APDS2, N = 256, was estimated by Kaplan-Meier analysis and plotted in panel C.

Figure 1






Figure 2






Figure 3

A



B



C

